St Anna Children's Hospital

Running trials

• Recruiting

  International Study for Treatment of Childhood Relapsed Precursor B-Cell ALL 2020 (IntReALL BCP 2020)

  NCT07476729· Phase 3· Charite University, Berlin, Germany· Source

• Recruiting

  Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)

  2025-521390-14-00· Phase 2· Pediatric Research International GmbH· Source

• Recruiting

  Study on chemotherapy and experimental drugs in patients with Philadelphia Chromosome positive and ABL-class Philadelphia Chromosome-Like B-cell Acute Lymphoblastic Leukemia

  2025-520982-39-00· Phase 3· Universita Degli Studi Di Milano Bicocca· Source

• Recruiting

  HEM-iSMART-C: Ruxolitinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  NCT05745714· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  HEM-iSMART-B: Dasatinib + Venetoclax + Dexamethasone + Cyclophosphamide and Cytarabine in Pediatric Patients With Relapsed or Refractory Hematological Malignancies

  NCT05751044· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  VyClo ITCC-092

  2023-508050-26-00· Phase 1· Prinses Maxima Centrum voor Kinderoncologie B.V.· Source

• Recruiting

  International open-label phase I dose escalation study of dinutuximab beta in combination with vincristine/doxorubicin/cyclophosphamide and ifosfamide/etoposide in pediatric, adolescent, and adult patients with GD2-positive Ewing sarcoma

  2024-515245-42-00· Phase 1· GPOH gGmbH· Source

• Recruiting

  Ziftomenib in Combination With Chemotherapy for Children With Relapsed/Refractory Acute Leukemia

  NCT06376162· Phase 1· PedAL BCU, LLC· Source

• Recruiting

  Therapeutic Drug Monitoring for Biological Therapy in Pediatric Inflammatory Bowel Disease

  NCT06954311· Medical University Innsbruck· Source

• Recruiting

  Establishment of a Novel Flow Cytometric Diagnostic Assay to Effectively Evaluate Immune Reconstitution After Hematopoietic Stem Cell Transplantation for Acute Lymphoblastic Leukemia

  NCT07899840· Fondazione Matilde Tettamanti Menotti De Marchi Onlus· Source

• Recruiting

  Study Combining Dinutuximab Beta With Two Chemotherapy Regimens in Neuroblastoma

  NCT06485947· Phase 1· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  A Multi-Arm, Platform Trial For Relapsed Neuroblastoma

  NCT07334301· Phase 1/2· University of Birmingham· Source

• Active, not recruiting

  LCH-IV International Collaborative Treatment Protocol for Children and Adolescents with Langerhans Cell Histiocytosis

  NCT02205762· Phase 2/3· St. Anna Childrens Cancer Research Institute GmbH· Source

• Recruiting

  A Global Study of Novel Agents in Paediatric and Adolescent Relapsed and Refractory B-cell Non-Hodgkin Lymphoma

  NCT05991388· Phase 2/3· University of Birmingham· Source

• Recruiting

  HEM iSMART-D: Trametinib + Dexamethasone + Chemotherapy in Children With Relapsed or Refractory Hematological Malignancies

  NCT05658640· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  A Study to Learn More About the Study Medicine Called Inotuzumab Ozogamicin (InO) in Children (1 to <18 Years) With First Relapse ALL

  NCT05748171· Phase 2· Pfizer· Source

• Recruiting

  Interfant-21 Treatment Protocol for Infants Under 1 Year With KMT2A-rearranged ALL or Mixed Phenotype Acute Leukemia

  NCT05327894· Phase 3· Princess Maxima Center for Pediatric Oncology· Source

• Active, not recruiting

  Venetoclax in Children With Relapsed Acute Myeloid Leukemia (AML)

  NCT05183035· Phase 3· PedAL BCU, LLC· Source

• Recruiting

  Brigatinib in Pediatric and Young Adult Patients With ALK+ ALCL, IMT or Other Solid Tumors

  NCT04925609· Phase 1/2· Princess Maxima Center for Pediatric Oncology· Source

• Recruiting

  International Euro Ewing (iEuroEwing) trial for treatment optimisation in patients with Ewing sarcoma

  2022-501180-40-00· Phase 3· GPOH gGmbH· Source

• Recruiting

  SIOP-HRMB: An international prospective trial on clinically high-risk medulloblastoma (HR-MB) in patients older than 3 years.

  2024-510578-25-00· Phase 3· The University Of Birmingham· Source

• Recruiting

  A Trial to Assess Haploidentical T-depleted Stem Cell Transplantation in Patients With SCD

  NCT04201210· Phase 2· University of Regensburg· Source

• Recruiting

  FaR-RMS: An Overarching Study for Children and Adults With Frontline and Relapsed RhabdoMyoSarcoma

  NCT04625907· Phase 1/2· University of Birmingham· Source

• Recruiting

  INFORM2 Study Uses Nivolumab and Entinostat in Children and Adolescents With High-risk Refractory Malignancies

  NCT03838042· Phase 1/2· University Hospital Heidelberg· Source

• Recruiting

  International study for children and adolescents with standard risk ALK-positive anaplastic large cell lymphoma (ALCL) estimating the efficacy of Vinblastine

  2022-501454-11-00· Phase 3· GPOH gGmbH· Source

• Recruiting

  SIOP RANDOMET 2017

  2023-508926-91-00· Phase 3· GPOH gGmbH· Source

• Recruiting

  High-Risk Neuroblastoma Study 2 of SIOP-Europa-Neuroblastoma (SIOPEN)

  NCT04221035· Phase 3· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Recruiting

  International Cooperative Treatment Protocol for Children and Adolescents With Lymphoblastic Lymphoma

  NCT04043494· Phase 3· University Hospital Muenster· Source

• Active, not recruiting

  Comparison of Carboplatin and Cisplatin in patients with extracranial malignant germ cell tumours

  2023-507582-25-00· Phase 3· Rheinische Friedrich-Wilhelms-Universitaet Bonn· Source

• Recruiting

  Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

  NCT03643276· Phase 3· Martin Schrappe· Source

• Recruiting

  International Study for Treatment of High Risk Childhood Relapsed ALL 2010

  NCT03590171· Phase 2· Charite University, Berlin, Germany· Source

• Active, not recruiting

  Paediatric Hepatic International Tumour Trial

  NCT03017326· Phase 3· University of Birmingham· Source

• Active, not recruiting

  Imatinib Mesylate and Combination Chemotherapy in Treating Patients With Newly Diagnosed Philadelphia Chromosome Positive Acute Lymphoblastic Leukemia

  NCT03007147· Phase 3· Children's Oncology Group· Source

• Active, not recruiting

  Treatment Protocol of the NHL-BFM and the NOPHO Study Groups for Mature Aggressive B-cell Lymphoma and Leukemia in Children and Adolescents

  NCT03206671· Phase 3· University Hospital Muenster· Source

• Recruiting

  Inotuzumab ozogamicin for Acute Lymphoblastic Leukemia

  2023-504694-20-00· Phase 1/2· Erasmus Universitair Medisch Centrum Rotterdam (Erasmus MC)· Source

• Recruiting

  rEECur: International Randomised Controlled Trial of Chemotherapy for the Treatment of Recurrent and Primary Refractory Ewing Sarcoma

  2024-516078-31-00· Phase 2/3· The University Of Birmingham· Source

• Recruiting

  Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia

  NCT01949129· Phase 2/3· St. Anna Kinderkrebsforschung· Source

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

• Childhood cancers25 recruiting
• Acute lymphoblastic leukaemia8 recruiting
• Sarcoma4 recruiting
• Neuroblastoma3 recruiting
• Acute myeloid leukaemia2 recruiting
• Hodgkin lymphoma1 recruiting
• Liver and biliary tract cancer1 recruiting
• Sickle cell disease1 recruiting
• Ulcerative colitis1 recruiting

Closed trials

• Completed

  A study to see how safe and effective the drug Luveltamab Tazevibulin (STRO-002) is in treating infants and children under 12 years old with a specific type of acute myeloid leukemia (AML)

  2023-506240-16-00· Phase 1/2· Sutro Biopharma Inc.· Source

• Completed

  Effects of maintenance cabozantinib+BSC versus BSC in children and AYA with osteosarcoma. ( CabOSTar )

  NCT06341712· Phase 2· Ipsen Innovation· Source

• Completed

  Quality Improvement Project - "My Logbook! - I Know my Way Around!"; ("Mein Logbuch - Ich Kenne Mich Aus!")

  NCT04474678· Medical University of Vienna· Source

• Active, not recruiting

  A Global Study of Midostaurin in Combination With Chemotherapy to Evaluate Safety, Efficacy and Pharmacokinetics in Newly Diagnosed Pediatric Patients With FLT3 Mutated AML

  NCT03591510· Phase 2· Novartis Pharmaceuticals· Source

• Completed

  Phase 1/2 Dose Finding and Safety Study of Ibrutinib in Pediatric Subjects With Chronic Graft Versus Host Disease (cGVHD)

  NCT03790332· Phase 1/2· Pharmacyclics LLC.· Source

• Terminated

  Evaluation of 2 Intensification Treatment Strategies for Neuroblastoma Patients With a Poor Response to Induction

  NCT03165292· Phase 2· Gustave Roussy, Cancer Campus, Grand Paris· Source

• Completed

  Second International Inter-Group Study for Classical Hodgkin Lymphoma in Children and Adolescents

  NCT02684708· Phase 3· University of Giessen· Source

• Completed

  Study of Carfilzomib in Combination With Induction Chemotherapy in Children With Relapsed or Refractory Acute Lymphoblastic Leukemia

  NCT02303821· Phase 1· Amgen· Source

Conditions

Diseases this institution publishes on or runs trials for.

• Acute lymphoblastic leukaemia20 works · 14 trials
• Neuroblastoma9 works · 5 trials